THE RESEARCH ON THE RECOMBINANT ADENO-ASSOCIATED VIRUS AS A VECTOR FOR THE GENE THERAPY OF LIVER CANCER
- VernacularTitle:重组腺病毒相关病毒作为肝癌基因治疗载体的初步研究
- Author:
Ziming LIU
;
Lünan YAN
;
Zhong WANG
- Publication Type:Journal Article
- From:
Chinese Journal of Bases and Clinics in General Surgery
2001;8(3):133-134
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the feasibility of recombinant adeno-associated virus (rAAV) as a vector for the gene therapy of liver cancer. Methods The rAAV/enhance green fluorescein protein (EGFP) recombinant was prepared by the routine method of two plasmids cotransfection. Results The experiment showed that one 10cm plate could produce 107-108 infection unit recombinant by the method of two plasmids cotransfection, and the transduction of HepG2 cell was increased with the increase of infection dosage of rAAV. About 100 multiplicity of infection (MOI) AAV vector could make all the tumor cell light. Conclusion Liver cancer cell can be efficiently transduced by rAAV, and AAV vector may be a valuable vector for the gene therapy of liver cancer.
